Gil RM, Freeman T, Mathew T, Kullar R, et al.  The LGBTQ+ communities and the COVID-19 pandemic: a call to break the cycle of structural barriers.  The Journal of Infectious Diseases July 2021

MacFarland LV, Kullar R., Maziade P, Goldstein EJC.  Why two studies using the same probiotic may have come up with different outcomes. Clinical Infectious Diseases July 2021

El-Sokkary R, Uysal S, Erdem H, Kullar R, et al. Profiles of multidrug-resistant organisms among patients with bacteremia in intensive care units: an international ID-IRI survey.  Eur J Clin Microbiol Infect Dis 2021 Jun 21

Geriak M, Haddad F, Kullar R, Greenwood K, Habib M, Habib C, Willms D, Sakoulas G. Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia. Infectious Diseases and Therapy 2021 May 11: 1-8

Kullar R., Johnson S, McFarland LV, Goldstein EJC. Potential Roles for Probiotics in the Treatment of COVID-19 Patients and Prevention of Complications Associated with Increased Antibiotic Use. Antibiotics 2021 Apr 9; 10(4): 408.

Haddad F, Lamb C, Kullar R, Somo M, Sakoulas G.  Point-Of-Care Clinical Evaluation of the Clungene® SARS-CoV-2 Virus IgG/IgM 15-minute rapid test cassette with the Cobas® Roche RT-PCR platform in patients with or without Covid-19.  LymphoSign 2021 (Accepted)

Dahal D, Sundar S, Kullar R, Milevska-Kostova N, Dindial K. Antimicrobial Resistance during the COVID-19 Pandemic: The Missing Patient Perspective.  JAC-AMR 2021; 3(1)

Kullar R, Patel AP, Saab S.  Hepatic Injury in Patients with COVID-19.  Journal of Clinical and Translational Hepatology Nov/Dec 2020; 54 (10): 841-849.

Sakoulas G, Geriak M, Kullar R, Greenwood KL, Habib M, Vyas A, Ghafourian M, Dintyala VNK, Haddad F.  Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019.  Crit Care Explor 2020 Nov 16;2 (11):e0280.

Kullar R, Tran MCN, Goldstein EJC.  Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI).  J Exp Pharmacol. 2020; 12:371-384.

Tan TQ, Kullar R, Swartz TH, Mathew TA, Piggott DA, Berthaud V. Location Matters: Geographic Disparities and Impact of Coronavirus Disease 2019 (COVID-19). Journal of Infectious Diseases September 2020.

Rahal H, Boutros S, Farhat M, Kullar R., Saab S. Estimating Pediatric Hepatitis C Prevalence in the United States. J Viral Hepat August 2020.

Kullar R., Saab S.  Hepatic Injury in Patients with COVID-19.  The Journal of Clinical Gastroenterology. Nov/Dec 2020; 54(10): 841-849.

Kullar R., Marcelin JR, Swartz TH, Piggott DA, Macias Gil R, Mathew TA, Tan T. Racial Disparity of Coronavirus Disease 2019 (COVID-19) in African American Communities. Journal of Infectious Diseases 2020 Aug 17; 222(6):890-893.

 Le L, Saleh H, Kullar R, Saab S. Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis. Digestive Diseases and Sciences 2020 Dec; 65 (12):3719-3725.

 Kim NG, Kullar R, Khalil H, Saab S. Meeting the WHO Hepatitis C Virus Elimination Goal: Review of Treatment in Pediatrics. J Viral Hepat 2020 Aug; 27(8): 762-769.

Kullar R, Goff DA, Gauthier TP, Smith TC. To Tweet or Not to Tweet-A Review of the Viral Power of Twitter for Infectious Diseases. Current Infectious Disease Reports 2020

Saab S, Kullar R, Gounder P. Universal Hepatitis Screening in Pregnant Women: A Call to Action.  Obstetrics & Gynecology March 2020

Saab S, Kullar R, Amini C, Gounder P. The Next Frontier: Universal HCV Screening in Pregnant Women.  American Journal of Obstetrics & Gynecology 2020 Feb 7. DOI: 10.1016/j.ajog.2020.01.058.

Kullar R, Johnson S, McFarland LV, Goff DA, Goldstein EJC. Bundling Probiotics with Antimicrobial Stewardship Programs (ASPs) for the Prevention of Clostridiodes difficile Infections (CDI) in Acute Care Hospitals. Infectious Diseases in Clinical Practice March 2020

Kullar R, Puzniak L, Swindle JP, Lodise T.  Retrospective Real-World Evaluation of Outcomes in Patients with Skin and Soft Structure Infections Treated with Tedizolid in an Outpatient Setting. Infect Dis Ther 2020 Jan 23. DOI: 10.1007/s40121-019-00279-0

McCreary E, Kullar R, et al.  Multicenter Cohort of Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia Receiving Daptomycin plus Ceftaroline Compared to Other MRSA Treatments.  Open Forum Infect Dis. 2019 Dec 31;7(1):ofz538. DOI: 10.1093/ofid/ofz538.

Goff DA, Kullar R. Can the Perfect Handshake Hold the Key to Success and Sustainability of Antimicrobial Stewardship Programs? Clin Infect Dis 2019 Oct 4. pii: ciz699.

Bauer KA, Kullar R, Gilchrist, M, File TM.  Antibiotics and Adverse Events: The Role of Antimicrobial Stewardship Programs in ‘Doing No Harm.’  Curr Opin Infect Dis 2019 Dec; 32(6): 553-558

Ha DR, Forte MB, Olans RD, OYong K, Olans RN, Gluckstein DP, Kullar R, Desai M, Catipon N, Ancheta V, Lira D, Khattak Y, Legge J, Nguyen KB, Chan S, Mourani J, McKinnell JA. A Multi-disciplinary Approach to Incorporate Bedside Nurses into Antimicrobial Stewardship and Infection Prevention. Jt Comm J Qual Patient Saf. 2019 Sep; 45(9): 600-605.

Tran MN, Kullar R, Goldstein EJC. Investigational drug therapies currently in early-stage clinical development for the treatment of clostridioides (clostridium) difficile infection. Expert Opinions on Investigational Drugs. 2019 Apr 28;(4):323-335. DOI: 10.1080/13543784.2019.1581763.

Kullar R et al. Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrobial Agents of Chemotherapy 2019 Apr 25;63(5). pii: e02483-18. DOI: 10.1128/AAC.02483-18.

Kullar R et al. A Multidisciplinary Approach to Incorporate Bedside Nurses into Antimicrobial Stewardship and Infection Prevention. Joint Commission Journal on Quality and Patient Safety. 2019 Apr 24. pii: S1553-7250(18)30391-X. DOI: 10.1016/j.jcjq.2019.03.003. DOI: 10.1097/GOX.0000000000001972

Goff DA, Kullar R, Laxminarayan R, Mendelson M, Nathwani D, Osterholm M. Twitter to engage, educate, and advocate for global antibiotic stewardship and antimicrobial resistance. Lancet Infectious Diseases 2019 Mar;19(3):229-231. DOI: 10.1016/S1473-3099(19)30058-1.

Kullar R, Frisenda J, Nassif PS. The More the Merrier? Should Antibiotics be Used for Rhinoplasty and Septorhinoplasty?—A Review. Plastic and Reconstructive Surgery – Global Open. 2018 October; 6(10): e1972.
DOI: 10.1097/GOX.0000000000001972

Kullar R, Nagel J, Bleasdale SC, Sutton SH, Naumovski S, Rodriguez A, Smith C, Leggett J, Goldstein EJC. Going for the Gold: A Description of ‘Centers of Excellence’ Designation by Infectious Diseases Society of America. Clinical Infectious Diseases 2018 Sep 18.
DOI: 10.1093/cid/ciy797

Co-author with National Quality Forum. Antibiotic Stewardship in Post-Acute and Long-Term Care Playbook.

Kullar R, Yang H, Grein J, Murthy R.  A Roadmap to Implementing Antimicrobial Stewardship Principles in Long-Term Care Facilities (LTCFs): Collaboration Between an Acute-Care Hospital and LTCFs.  (Invited Article).  Clinical Infectious Diseases 2018 Apr 3;66(8):1304-1312. DOI: 10.1093/cid/cix1041

Goff DA, Kullar R, Bauer K, File T.  Eight Habits of Highly Effective Antimicrobial Stewardship Programs to Meet the Joint Commission Standards for Hospitals. (Invited Article). Clinical Infectious Diseases 2017 Apr 15;64(8):1134-1139. DOI: 10.1093/cid/cix065

Xiao AJ, Caro L, Popejoy MW, Huntington JA, Kullar R.  PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease. Infect Dis Ther. 2017 March; 6 (1): 137-148.

Kullar R., Wagenlehner F., Popejoy M.W., Long J., Yu B., Goldstein E.J.  Does Moderate Renal Impairment Affect Clinical Outcomes in Complicated Intra-Abdominal and Complicated Urinary Tract Infections? – Analysis of Two Randomized, Controlled Trials with Ceftolozane/Tazobactam.  Journal of Antimicrobial Chemotherapy.  2016 Dec 20.

Goff DA, Kullar R, Goldstein EJ, Gilchrist M, Nathwani D, Cheng AC, Cairns KA, Escandón-Vargas K, Villegas MV, Brink A, van den Bergh D, Mendelson M.  A Global Call From Five Countries to Collaborate in Antibiotic Stewardship: United We Succeed, Divided We Might Fail. (Invited Article). Lancet Infect Dis. 2016 Nov 17. DOI: https://doi.org/10.1016/S1473-3099(16)30386-3

Kullar R, Sakoulas G, Deresinksi S, van Hal SJ. When Sepsis Persists: A Review of MRSA Bacteraemia Salvage Therapy.  (Invited Article). J Antimicrob Chemother 2016 Mar; 71 (3) 576-86.

Kullar R, Vassallo A, Turkel S, Chopra T, Kaye KS, Sobrah Dhar.  “Degowning” the Controversies of Contact Precautions (CP) for Methicillin-Resistant Staphylococcus aureus (MRSA): A Review.  (Invited Article). American Journal of Infection Control 2016 Jan 1; 44 (1): 97-103.

Casapao AM, Lodise TP, Davis S, Claeys KC, Kullar R, Levine DP, Rybak MJ.  The Association between the Vancomycin Day 1 Exposure Profile and Outcomes Among Patients with Methicillin-Resistant Staphylococcus aureus Infective Endocarditis. Antimicrobial Agents of Chemotherapy 2015; 59 (6): 2978-85.

Goff DA, Kullar R, Newland JG.  Review of Twitter for Infectious Diseases Clinicians: Useful or a Waste of Time?  (Invited Article). Clinical Infectious Diseases 2015 May 15; 60 (10): 1533-40. DOI:10.1093/cid/civ071

Sakoulas G, Nonejuie P, Kullar R, Pogliano J, Rybak M, Nizet V.  Examining the Use of Ceftaroline in the Treatment of Streptococcus pneumoniae Meningitis with Reference to Human Cathelicidin LL-37.  Antimicrobial Agents of Chemotherapy 2015 April; 59(4): 2428-31.

Kullar R., McKinnell J.A., Sakoulas G. Avoiding the Perfect Storm: The Biologic and Clinical Case for Reevaluating the 7-Day Expectation for Methicillin-Resistant Staphylococcus aureus Bacteremia Before Switching Therapy. (Invited Article). Clinical Infectious Diseases 2014 Nov 15;59(10):1455-61.

Forrest GN, Van Schooneveld TC, Kullar R, Schulz LT, Duong P, Postelnick M.  Use of Electronic Health Records and Clinical Decision Support Systems for Antimicrobial Stewardship.  Clinical Infectious Diseases 2014 Oct 15;59 Suppl 3:S122-33. DOI: 10.1093/cid/ciu565

Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, Rybak MJ, Kullar R, Dhand A, Rose WE, Goff DA, Bressler AM, Lee Y, Pogliano J, Johns S, Kaatz GW, Ebright JR, Nizet V.  Antimicrobial Salvage Therapy for Persistent Staphylococcal Bacteremia using Daptomycin plus Ceftaroline.  Clinical Therapeutics 2014 Oct 1;36(10):1317-33.

Casapao A, Davis S, McRoberts J, Lagnf A, Patel S, Kullar R, Levine D, Rybak M. Evaluation of Vancomycin Population Analysis Profile Susceptibility as a Predictor of Patient Outcomes with Methicillin-Resistant Staphylococcus aureus Infective Endocarditis. Antimicrobial Agents of Chemotherapy 2014 Aug; 58(8): 4636-41.

Kullar R., Goff D.A.  Transformation of Antimicrobial Stewardship Programs through Technology.  (Invited Article and chapter in book).  Infectious Disease Clinics of North America 2014 Jun; 28(20): 291-300. DOI: 10.1016/j.idc.2014.01.009

Kullar R., McClellan I., Geriak M., Sakoulas G. Efficacy and Safety of Daptomycin in Patients with Renal Impairment: A Multicenter Retrospective Analysis. Pharmacotherapy 2014 Jun; 34(6): 582-9.

Kullar R., Casapao A, Davis SL, Levine DP, Zhao J, Crank C, Segreti J, Sakoulas G,  Cosgrove S; Rybak MJ. A Multicentre Evaluation of the Effectiveness and Safety of High-Dose Daptomycin for the Treatment of Infective Endocarditis.  Journal of Antimicrobial Chemotherapy 2013 Dec; 68(12): 2921-6.

Bubalo J., Kullar R., Maziarz R.  A Pilot Study of the Efficacy and Safety of Empiric Daptomycin Therapy in Oncology Patients with Fever and Severe Neutropenia. Therapeutic Advances in Infectious Disease 2013 Dec; 1(6): 183-90.

Casapao A., Kullar R., Davis SL, Levine DP, Zhao J, Potoski B, Goff D, Crank C, Segreti J, Sakoulas G, Rybak MJ.  Multicenter Study of High-Dose Daptomycin for Treatment of Enterococcal Infections. Antimicrobial Agents of Chemotherapy 2013 Sep; 57(9): 4190-6.

Kullar R., Goff D.A., Schulz LT, Fox B.C., Rose W.E.  The “Epic” Challenge of Optimizing Antimicrobial Stewardship: the Role of Electronic Medical Records and Technology. (Invited Article).  Clinical Infectious Diseases 2013 Oct; 57(7): 1005-13. DOI: 10.1093/cid/cit318

Kullar R., Rybak M.J., Kaye K.S.  Comparative Epidemiology of Bacteremia due to Methicillin-Resistant Staphylococcus aureus (MRSA) Between Older and Younger Adults: a Propensity Score Analysis. Infection Control and Hospital Epidemiology 2013 April; 34 (4): 400-6.

Murray K.P., Zhao J.J., Davis S.L., Kullar R., Kaye K.S., Lephart P., Rybak M.J. Early Use of Daptomycin Versus Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia With Vancomycin Minimum Inhibitory Concentration >1 mg/L: A Matched Cohort Study.  Clinical Infectious Diseases 2013 June; 56 (11): 1562-9.

Levine P.J., Elman M.R., Kullar R., Townes J.M., Bearden D.T., Vilches-Tran R., McClellan I., McGregor J.C.  Use of Electronic Health Record Data to Identify Skin and Soft Tissue Infections in Primary Care Settings: a Validation Study. BMC Infectious Diseases 2013 April 10; 13 (1): 171.

Kullar R., Davis S.L., Kaye K.S., Levine D.P., Pogue J., Rybak M.J.  Implementation of an Antimicrobial Stewardship Pathway with Daptomycin for Optimal Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.  Pharmacotherapy 2013 January; 33(1): 3-10.

Kullar R., Davis S.L., Kaye K.S., Taylor T.N., Rybak M.J.  Evaluation of targeting higher vancomycin troughs on costs and clinical outcomes in a matched cohort of patients. Pharmacotherapy 2012; 32 (2).

Kullar R., Davis S.L., Levine D.P., Rybak M.J. Impact of vancomycin exposure on outcomes of patients with MRSAB: Verification of consensus guidelines suggested targets. Clinical Infectious Diseases 2011; 52 (8): 975-81.

Kullar R., Chin J.N., Edwards D.J., Coplin W.M., Parker D., Rybak M.J.  Central nervous system penetration and pharmacodynamics of daptomycin in neurological infections. Antimicrobial Agents of Chemotherapy 2011; 55 (7): 3505-9.

Kullar R., Leonard S., Davis S., Delgado G., Wahby K., Pogue J., Falcione B., Rybak M.J. Validation of a high-trough vancomycin nomogram to achieve trough concentrations of 15 to 20 mg/L.  Pharmacotherapy 2011; 31 (5): 441-48.

Kullar R., Davis S.L., Levine D.P., Zhao J., Crank C.W., Segreti J., Sakoulas G., Cosgrove S.E., Rybak M.J.  Large multi-center case-series analysis of high-dose daptomycin for complicated Gram-positive infections. Pharmacotherapy 2011; 31 (6): 527-36.

Kullar R., New Drugs for Bad Bugs. Invited Speaker Infectious Diseases Association of California (IDAC) Winter Symposium; Oakland, CA; March 7, 2020

Kullar R.  Coronavirus.  Invited Expert on Entertainment Today. March 2, 2020. https://www.etonline.com/coronavirus-dr-ravina-kullar-talks-vaccines-medical-masks-and-more-tips-for-staying-healthy-142436

Kullar R. Coronavirus. Invited Podcast Infectious Diseases Society of America (IDSA). February 28, 2020. https://soundcloud.com/idsociety/covid19-podcast-feb-28/s-KMPqg

Kullar R., Goldstein EJC. Handling Outbreaks in Long-Term Care Facilities (LTCFs). Invited SHEA Podcast December 2019. https://soundcloud.com/user-788310625/prevention-and-control-of-outbreaks-in-long-term-care/s-CGE4E?in=user-788310625/sets/infection-control-in-long-term

Kullar R., et al. Bedside Nurses Improve Antimicrobial Stewardship and Infection Prevention Outcomes: Results of a 3.5-year Study in Three Hospital Telemetry Units; Session 239; Poster #2085. ID Week October 2-6, 2019: Washington, DC.

Kullar R. Infection Control and Hospital Epidemiology Bundling Probiotics with Antimicrobial Stewardship Programs (ASPs) for the Prevention of CDI in Acute Care Hospitals; ID Week October 2-6, 2019: Washington, DC.

Invited Keynote Speaker at 72nd World Health Assembly; “Time for Concrete Action: Addressing the Global Antimicrobial Resistance (AMR) crisis”; Side-event Co-organized by the Global Antibiotic Research and Development Partnership (GARDP) and the World Health Organization (WHO); May 21, 2019; Geneva, Switzerland

Kullar R. The Antibiotic Apocalypse: Superbugs vs. Humans; Invited TED Speaker; March 9, 2019; London, UK. https://youtu.be/JS6_UplxNc0

Kullar R. Becoming a Steward in Long-Term Care Facilities; Invited Speaker for MAD-ID Online Antimicrobial Stewardship (AMS) Teaching Modules; November 2018.

Kullar R. The Antibiotic Resistance Crisis: How to be a part of the solution; Invited TED Speaker; September 26, 2018; Detroit, MI https://youtu.be/JS6_UplxNc0

Kullar R. Understanding the crisis and how you can prevent a future pandemic; Invited TED Speaker; March 31, 2018; Bend, OR. https://youtu.be/tGtYvQCSfFA

Jayakumar R., Leuthner K., Kullar R., Puzniak L. Real-world evaluation of ceftolozane/tazobactam (C/T) in severely ill patients with sepsis and/or bacteraemia. Accepted poster ECCMID (Abstract #6855); April 21-24, 2018; Madrid, Spain

Kullar R. Antibiotic Resistance: Understanding the crisis and how you can prevent a future pandemic; Invited TED Speaker; March 31, 2018; Bend, OR

Kullar R. Invited speaker for Infectious Diseases Association for California (IDAC). How to Meet The Joint Commission (TJC) 8 Antimicrobial Stewardship Standards. Berkeley, CA; March 3, 2018.

Kullar R. Invited speaker for Los Angeles Department of Public Health – Antibiotics Awareness Week. Meeting The Joint Commission 8 Antimicrobial Stewardship Standards and Overcoming Common Barriers in Your Stewardship Program. Los Angeles, CA; November 13, 2017.

Yang H., Kullar R., Grein J., Murthy R. Partners in Stewardship: Collaboration Between a Tertiary Hospital and Local Skilled Nursing Facilities to Improve Management of Suspected Urinary Tract Infections. Accepted poster ID Week; October 4-8, 2017; San Diego, CA

Leuthner K.D., Kullar R., Jayakumar R., Hewlett D.A, Nguyen T., Puzniak L. Real World Evaluation of Ceftolozane/Tazobactam (C/T) Use and Clinical Outcomes at an Academic Medical Center in Las Vegas. Accepted poster ID Week; October 4-8, 2017; San Diego, CA

Davis A., Hermsen E.D., Kullar R., Oakley L., Roberts Y., Puzniak LA. Impact of Use of Fidaxomicin (FDX) in a Treatment Algorithm for Clostridium difficile Infection (CDI) in Hospitalized Patients at High Risk for Recurrence. Wellstar Hlth.System, Austell, GA, Merck & Co., Inc., Kenilworth, NJ. Accepted poster American Society for Microbiology (ASM); June 1-6, 2017; New Orleans, LA

Kullar R., Rastogi A., Saidian J., Li A., Asaturyan A., Hanna M., Joseph E., Puzniak L. Treatment management and outcomes in patients with Clostridium difficile infection (CDI): assessing the impact of renal disease. Accepted poster European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); April 22-25, 2017; Vienna, Austria

Rastogi A., Kullar R., Alipourfetrati S., Arman F., Hanna H.S., Faiek S., Puzniak L. The Interplay between Clostridium difficile Infection (CDI) and Renal Disease: Epidemiology, Treatment Management and Outcomes. Division of Nephrology, Dept of Medicine, University of California, Los Angeles, Los Angeles, CA; Center of Observational and Real World Evidence, Merck & Co, Inc, Kenilworth, NJ. Accepted poster American Society of Nephrology; November 15-20; Chicago, IL

Kullar R., Merchant S., Tabak Y.P., et al. Regional and Source Variations in Vancomycin-resistant Enterococci (VRE) Rates in US Hospitals 2015. Accepted poster Infectious Disease (ID) Week; October 27, 2016

Kullar R., De Anda C., Anuskiewicz S., Prokocimer P. Outpatient Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSI) with Tedizolid Phosphate and Linezolid in Patients in the United States. Accepted poster Antimicrobial Society of Microbiology (ASM) Microbe; June 18, 2016

Kullar R. Invited speaker for Infectious Diseases Association for California (IDAC). Components of an Effective ASP Informatics Program: Essential Elements and Helpful Enhancements. Berkeley, CA; March 4, 2016.

Kullar R. Invited speaker for Infectious Diseases Association for California (IDAC). Components of an Effective ASP Informatics Program: Essential Elements and Helpful Enhancements. Irvine, CA; July 18, 2015.

Kullar R. Invited speaker for Infectious Diseases Association for California (IDAC). Electronic health records (EHRs) and the I.D. clinician. Oakland, CA; March 15, 2014.

Kullar R. Invited speaker for Association for Professionals in Infection Control and Epidemiology (APIC). The role of rapid diagnostics in antimicrobial stewardship. Los Angeles, CA; February 25, 2014.

Kullar R., Markwardt S., Forrest G. Epidemiology and Treatment of Vancomycin-Resistant Enterococcal Infections: Efficacy and Safety Comparison of Daptomycin and Linezolid. Poster presentation at ECCMID April 27-30, 2013; Berlin, Germany.

Kullar R. Overuse of Antibiotics and the Evolution of a new Superbug, Clostridium difficile; Oregon Academy of General Dentistry (OAGD). 2012 meeting October 13, 2012; Newburg, OR.

Kullar R., McClellan I., Geriak M., Sakoulas G. Efficacy and Safety of Daptomycin in the Treatment of Gram-Positive Infections in Patients with Renal Impairment. Poster presentation at ICAAC September 8-12, 2012; San Francisco, CA.

Kullar R., Rybak M.J., Kaye K.S. Comparative Epidemiology of Bacteremia due to Methicillin-Resistant Staphylococcus aureus (MRSA) Between Older and Younger Adults: A Propensity Score Analysis. Poster presentation at ICAAC September 8-12, 2012; San Francisco, CA.

Kullar R., Garber J., Alhadab A., Olyaei A., Allada G., Gold J., Munar M.J. Piperacillin-Tazobactam (PT) Extended Infusion (EI) Therapy to Treat Pulmonary Exacerbations in Patients with Cystic Fibrosis. Poster presentation at ICAAC September 8-12, 2012; San Francisco, CA.

Casapao A., Kullar R., Patel S., Rybak M.J. Evaluation of Population Analysis Profile Susceptibility (PAP) as a Predictor of Patient Outcomes with Methicillin-Resistant Staphylococcus aureus (MRSA) Infective Endocarditis (IE). Poster presentation at ICAAC September 8-12, 2012; San Francisco, CA.

Casapao A., Kullar R., Davis S.L., Levine D.P., Zhao J., Goff D., Sakoulas G.,Cosgrove S.E., Rybak M.J. High-Dose Daptomycin for Treatment of Enterococcal Infections: Multicenter, Retrospective Study. Poster presentation at ICAAC September 8-12, 2012; San Francisco, CA.

Murray K.P., Kullar R., Davis S.L., Rybak M.J. Daptomycin vs. vancomycin MIC > 1 mg/L in a matched cohort of patients with MRSAB. Platform presentation at ICAAC September 8-12, 2012; San Francisco, CA.

Kullar R. The Hidden Costs of Treating MRSA: Economic and Clinical Implications. Invited speaker annual Oregon Society of Health-System Pharmacists (OSHP) 2012 meeting April 18-20, 2012; Sunriver, OR.

Kullar R., Chin J.N., Parker D., Coplin W.M., Edwards D.J., Rybak M.J. Central nervous system penetration and pharmacokinetcs of daptomycin in neurological infections. Platform presentation at ICAAC September 12-15, 2010; Boston, MA.

Kullar R., Davis S.L., Pogue J.M., Zhao J.J., Levine D.P., Kaye K.S., Rybak M.J. Evaluation of a clinical pathway for the treatment of MRSA bacteremia with an MIC of >1 mg/L to vancomycin. Poster presentation at ICAAC September 12-15, 2010; Boston, MA.

Kullar R., Davis S.L., Levine D.P., Rybak MJ. Vancomycin trough concentrations and outcomes in patients with MRSA infective endocarditis. Poster Walk Oral presentation at ICAAC September 12-15, 2010; Boston, MA.

Kullar R., Davis S.L., Levine D.P., Zhao J.J., Crank C.W., Cosgrove S.E., Segreti J., Rybak M.J. High-dose daptomycin for infective endocarditis. Platform presentation at ECCMID April 10-13, 2010; Vienna, Austria.

Kullar R., Davis S.L., Kaye K.K., Taylor T., Rybak M.J. Cost and outcome implications of the newly developed high-dose vancomycin consensus guidelines. Poster presentation at ECCMID April 10-13, 2010; Vienna, Austria. Abstract # 2772; Encore presentation at MAD-ID May 6-8, 2010; Orlando, FL.

Kullar R., Davis S.L., Levine D.P., Zhao J.J., Crank C.W., Cosgrove S.E., Segreti J., Rybak M.J. High-dose daptomycin for enterococcal infections. Poster presentation at IDSA October 29-November 1, 2009; Philadelphia, PA. Abstract # 895.

Kullar R., Davis S.L., Levine D.P., Zhao J.J., Crank C.W., Cosgrove S.E., Segreti J., Rybak M.J. Safety of high-dose daptomycin for Gram-positive infections. Poster presentation at ICAAC September 12-15, 2009; San Francisco, CA. Abstract # 1983.

Kullar R., Bhan R., Davis S.L., Rybak M.J. Outcomes of patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Platform presentation at ICAAC September 12-15, 2009; San Francisco, CA.

Kullar R., Davis S.L., Levine D.P., Zhao J.J., Crank C.W., Cosgrove S.E., Segreti J., Rybak M.J. High-dose daptomycin for complicated Gram-positive infections. Poster presentation at ECCMID May 16-20, 2009; Helsinki, Finland. Abstract #P1986; 6th Annual Research Forum Eugene Applebaum College of Pharmacy and Health Sciences September 9, 2009.

Patel S., Kullar R., Davis S.L., Steed M.E., Rybak M.J. Evaluation of population analysis profile susceptibility as a predictor of patient outcome in patients with MRSA infective endocarditis. Poster presentation at the 6th Annual Research Forum Eugene Applebaum College of Pharmacy and Health Sciences September 9, 2009.

Kullar R., Leonard S., Davis S., Delgado G., Wahby K., Pogue J., Sheth A., Shah P., Falcione B., Rybak M. Validation of a high-trough vancomycin nomogram to achieve trough concentrations of 15 to 20 mg/L. Poster presentation at ECCMID May 16-20, 2009; Helsinki, Finland. Abstract # P1982.

Kullar R., Davis S., Rybak M. New vancomycin guidelines in relationship to patients with MRSA bacteremia. Poster Presentation at Staphylococcus Symposium March 11-14, 2009; Honolulu, Hawaii.

Kullar R., Davis S.L., Rybak M.J., Kaye K.S. Comparative epidemiology of MRSA bacteremia between older and younger adults. Poster presentation at SHEA March 19-22, 2009; San Diego, CA.